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Hospitalizations and mortality 
among patients with fetal alcohol 
spectrum disorders: a prospective 
study
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With nearly 10% of women consuming alcohol during pregnancy, fetal alcohol spectrum disorders 
(FASDs) are becoming an increasing concern for clinicians and policymakers interested in the field of 
healthcare. Known as the range of mental and/or physical disabilities that occur among individuals 
with prenatal alcohol exposure, FASDs can result in dysmorphic features, problems with physical 
growth, neurobehavioral and cognitive problems that not only increase risk of various diseases, but 
also premature mortality. We investigated whether the diagnosis of FASDs result in increased risk of 
hospitalizations and mortality, with respect to FASD domains and relative diseases, when age effects 
are controlled for. The data for this study was taken from the National Health Insurance Service – 
National Sample Cohort (NHIS‑NSC) between 2003 and 2013. The population attributable risk (PAR) 
statistic was used to estimate the percentage of hospitalizations and mortality attributable to FASDs 
and other factors. A time‑dependent Cox proportional hazards model with age of diagnosis as the 
time‑scale was employed to calculate adjusted hazard ratios and 95% CIs for hospitalizations and 
mortality among FASD populations compared to their general population peers. Among the 3,103 
FASD cases, 27.5% experienced hospitalizations and 12.5% died. Overall, FASDs accounted for 853 
FASD‑attributable hospitalizations (51.0% of all hospitalizations in the study population) and 387 
mortality events (34.5% of all deaths in the study population). 20.52% of hospitalizations and 21.35% 
of mortalities were attributable to FASDs in this population. Compared to the control group, FASD 
patients had a 1.25‑fold (HR: 1.25, 95% CI: 1.05–1.49, p = 0.0114) increased risk of hospitalizations 
and a 1.33‑fold (HR: 1.33, 95% CI: 1.07–1.67, p = 0.0118) increased risk of all‑cause mortality. The most 
common cause for hospitalization was diseases of the nervous system, which accounted for 450 FASD‑
attributable hospitalizations (96.2% of all nervous system hospitalizations in the study population). 
In fact, FASD patients were 52 times more likely to be hospitalized for nervous system diseases than 
their peers (HR: 51.78, 95% CI: 29.09–92.17, p < .0001). The most common cause for mortality was 
neoplasms, which accounted for 94 FASD‑attributable deaths (28.7% of all neoplasm deaths in the 
study population). However, FASD patients did not have increased risk of neoplasm mortality than the 
general population (HR: 0.88, 95% CI: 0.59–1.32, p < .0001). Overall, this study found that individuals 
diagnosed with FASDs have increased risk of both hospitalizations and mortality, compared to their 
general population peers. This is particularly so for diseases of the nervous system, which showed a 
52‑fold increase in hospitalizations and four‑fold increase in mortality for FASD patients in our study. 
Likewise, while the association between FASDs and neoplasm mortality was not significant in our 
investigation, more attention by neurologists and related healthcare providers regarding the link 
between these two factors is necessary.
Trial Registration: Institutional Review Board of Yonsei University’s Health System: Y‑2019‑0174.
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With reports that 9.8% of women consume alcohol during pregnancy, an increasing concern in the field of 
healthcare is the development of fetal alcohol spectrum disorders (FASD). FASDs are the range of mental and/
or physical disabilities that can occur among all individuals with prenatal alcohol exposure. Systematically 
assessed according to various domains (dysmorphic features, physical growth, neurobehavioral development, and 
prenatal alcohol exposure)1, FASDs can result in a range of lifelong adverse outcomes, as well as increased risk 
for  mortality2,3. Moreover, many problems that are associated with prenatal alcohol exposure are not currently 
considered on the FASD continuum, including isolated growth impairments, speech and language impairments, 
and vision  impairments4. Such multimorbidity, deriving from prenatal alcohol exposure, is considered to be the 
leading preventable cause of congenital defects and mental impairment in the  world5.
Unfortunately, the exact prevalence rate of FASDs is difficult to predict. Not only is alcohol consumption 
during pregnancy underreported, healthcare providers often misdiagnose or underdiagnose FASDs due to a lack 
of knowledge regarding diagnostic procedures and treatment  recommendations3,6. Furthermore, while most 
cases of FASDs cannot be identified in infancy, no useful diagnostic criteria for FASD diagnosis among adults 
or the elderly  exist7. Only the diagnostic criteria for infants, which is not predicative of FASD prevalence rates 
in childhood or adult life, allow us to estimate that FASDs occur among one in 13 prenatally exposed  infants6.
Regionally, the prevalence estimate of alcohol use during pregnancy is highest in the European region (EUR) 
(PE: 25.2%, 95% CI: 21.6–29.6), followed by the region of the Americas (AMR) (PE: 11.2%, 95% CI: 9.4–12.6), 
African region (AFR) (PE: 10.0%, 95% CI: 8.5–11.8), Western-Pacific region (WPR) (PE: 8.6%, 95% CI: 4.5–11.6), 
South-East Asia region (PE: 1.8%, 95% CI: 0.9–5.1), and Eastern-Mediterranean region (EMR) (PE: 0.2%, 95% 
CI: 0.1–0.9)8. As such, the prevalence estimate of FASD by 10,000 persons are as follows: EUR (PE: 198.2, 95% CI: 
140.9–280.0), AMR (PE: 87.9, 95% CI: 63.7–132.4), AFR (PE: 78.3, 95% CI: 53.6–107.1), WPR (PE: 67.4, 95% CI: 
45.4–116.6), SEAR (PE: 14.1, 95% CI: 6.4–53.1), and EMR (PE: 1.3, 95% CI: 0.9–4.5)9. In the case of South Korea, 
previous studies have reported that around 13% to 16% of women are reported to drink during  pregnancy10.
Current evaluations of the socio-economic costs of FASDs state that significant charges are also involved 
pertaining to healthcare, special education, residential care, the criminal justice system, productivity losses due 
to various comorbidities and diseases, premature mortality, and productivity losses due to caregiving of  patients11.
As see in a systematic review of thirty-two studies from 4 countries (United States [n = 20], Canada [n = 9], 
Sweden [n = 2], and New Zealand [n = 1]), annual per-person costs of care can range from $22,810 per child to 
$24,308 per adult globally, which exceed costs for autism by 26%, asthma by 87%, diabetes by 13% and epilepsy 
by 56%11. Considering that around 630,000 new cases of FASDs are predicted to occur each year, this is a sig-
nificantly costly problem warranting investments in prevention and treatment.
Although some studies have attempted to measure the complications associated with prenatal and primary 
care during  pregnancy12, few recent studies have measured the prevalence and causes of hospitalizations in 
FASD population. What is known is that compared to their general population peers, children with FASDs are 
hospitalized more often for failure to thrive, neglect, anemia, child sexual abuse, and feeding problems and are 
often diagnosed with otitis media, pneumonia, dehydration, and  anemia13.
Regarding premature mortality, previous studies have found that prenatal alcohol exposure is a powerful 
risk marker for spontaneous abortions, stillbirths, miscarriages, and deaths in  general14. In a study comparing 
the mortality rates of siblings of children with FASDs and their general population peers, it was found that the 
siblings group’s mortality rate increased by 530%15. In another study comparing the mortality rates of subjects 
with FASDs and their same-age peers, cases with FASDs were at nearly five times the mortality risk for both 
children and  adults16. Lastly, in a study of 175 human PNAE and FASD autopsy brains, Jarmasz et al. (2017) 
found placental abnormalities in at least 68% of fetal and infant cases, as well as various brain malformations 
including micrencephalies (17.8%), neural tube defects (3.4%), and minor leptomeningeal heterotopia (3.4%) 
among all  subjects17.
Unfortunately, few studies have focused on the exact causes of mortality that occur among these groups in 
detail, especially in comparison to general population groups. Furthermore, types of FASDs pertaining to spe-
cific effects: fetal alcohol  syndrome18, partial FAS (PFAS), static encephalopathy/alcohol exposed (SE/AE), and 
neurobehavioral disorder/alcohol exposed (ND/AE), and their respective associations with mortality have not 
been researched in-depth19.
Numerous comorbidities have been associated with prenatal alcohol exposure of the fetus and increased 
mortality risk. Conditions associated with the peripheral nervous system and special senses, conduct disorder, 
receptive language disorder, chronic serious otitis media, and expressive language disorders have shown to be 
especially prevalent with pooled estimates exceeding 50% of patients with FAS in certain studies (Table 1)20.
Thus, medical expenditures that arise from such hospitalizations for children with FAS are noticeably higher 
than that of their general population peers. For example, a previous study reported that the annual mean medi-
cal expenditures of children with FAS are nine times higher than those of children without FASDs ($16,782 vs. 
$1,895)21. While most visits are outpatient visits in nature, FAS patients visit for inpatient services a lot more 
than their general population peers (31.3% vs. 17.2%)21.
Previous studies state that the cause-specific mortality rates of diseases on the FASD continuum contribute 
to around 6% of all deaths  annually22. Causes range from external, including suicides and accidents, to internal, 
including diseases of the nervous and respiratory systems, digestive system, congenital malformations, mental 
and behavioral disorders, and diseases of the circulatory  system23.
In other studies, malformations of the heart, brain malformations, including microcephaly, hydrocephaly, 
porencephaly etc.), sepsis, kidney malformations, and cancer were the most prevalent causes of death, especially 
among newborn in their first year of life, in which over half of all deaths  occurred24.
Depending on early diagnosis and support, life expectancies can increase; however, on average, people with 
FAS are estimated to live 34 years (95% CI: 31–37 years), which is around 42% of the life expectancies of their 
general population  peers23. Although initial diagnosis must be confirmed as early as possible to provide entry into 
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intervention programs associated with improved outcomes, lack of an early diagnosis remains one of the strong-
est outcomes associated with disrupted school experience, trouble with the law, confinement in detention,  jail25.
Thus, this study aimed to examine the mortality risk of patients with FASDs compared to their general 
population peers. Additionally, this study analyzed the effects of various sociodemographic characteristics on 
the impact of all-cause and cause-specific mortality, stratified by FASD domains.
Materials and methods
Data and study population. The data used in this study were obtained from the National Health Insur-
ance Service National Sample Cohort (NHIS-NSC) for the years 2003 to 2013. This data was constructed with 
the sole purpose of providing public health researchers and policy makers with representative, useful informa-
tion regarding Korean citizens’ utilization of health insurance and health examinations.
To construct the cohort, a representative sample cohort of 1,109,938 participants, representative of 2.2% 
of the Korean population, were randomly selected and followed for 11 years. During the follow-up period, a 
representative sample of newborns was added annually and all deceased or emigrated participants, excluded.
From these participants, we extracted 3,103 individuals who were classified as having FASDs by healthcare 
professionals from the database, using the ICD-10 codes for FASDs, standardized by the American Academy 
of Pediatrics.
While the ICD-10 diagnoses was employed in our study, it must be noted that the use of electronic health 
records (EHRs) in FASD diagnoses has numerous problems including the lack of a specific code or gold standard 
for the identification of FAS, and the reticence of physicians to make the diagnosis of FASDs due to the various 
social stigmas it may imply and/or difficulties in identification of  characteristics26. Controls were selected ran-
domly from the 1,106,835 individuals without a diagnosis of FASDs in our study period (Fig. 1).
Measures. The dependent variables of this study were hospitalizations and all-cause mortality, as well as 
type of hospitalization and mortality from other causes. Only hospitalizations and/or mortality cases occurring 
within the study period, following the time-dependent exposure of FASD diagnosis were seen as events. Hospi-
talization and death codes were classified according to ICD-10 chapters, excluding codes for FASDs, as done so 
in the existing body of  literature27. The independent variable in this study was the diagnosis of FASDs, compared 
to general population peers. In our analysis, the diagnosis of FASDs was a time-dependent covariate; resulting in 
the censoring of any event occurring before the diagnosis of FASDs to prevent time-dependent bias.
Covariates controlled for while investigating the association between prevalence of FASDs and mortality 
included sex, income, medical insurance, disability, disability severity, disability type, level of psychatric treat-
ment, Charlson Comorbidity Index  Score28, region, and year of cohort entry.
Statistical analysis. Chi-squared tests and univariate analysis were conducted to examine the distribu-
tion of the general characteristics of the study population, with regard to cases, controls, and the total popula-
tion. General characteristics were reported through frequencies and percentages. The population attributable 
risk (PAR) statistic was used to estimate the percentage of hospitalizations and mortality that could be attrib-
uted to FASDs and other factors in this population. This was calculated on the basis of the following formula: 
PAR = (p[r − 1]/(p[r − 1] + 1) × 100.
To calculate the association between FASD diagnosis and the risks of hospitalizations and mortality, a time-
dependent Cox’s proportional hazards regression model was employed to calculate adjusted hazard ratio (HR) 
and 95% CI (confidence interval) values.
While the most common time scale for Cox’s proportional hazards analyses is follow-up period with adjusted 
baseline entry age, this study employed attained age as the time scale with left truncated data. Many studies have 
recently argued that in time-on studies where follow-up period is tracked from cohort entry to a certain event 
(e.g. death), the effect of age is not tightly controlled  for29. For example, if follow-up period is employed as the 
time scale, a child patient may have the same time scale as a middle-aged or elderly patient, who was admitted 
to the cohort for the same length of time. By employing age as our time scale, our study was able to calculate 
age-specific incidence functions, with flexible control for the effects of age.
In our study, age at recruitment of study was defined as the first admission into our cohort for both cases and 
controls. Because the NHIS-NSC categorizes the ages of individuals into groups of 5, median age was used to 
Table 1.  ICD-10 Codes for FASDs (10th Revision)55.
Code Description
P04.3 Newborn (suspected to be) affected by maternal use of alcohol (excludes FAS)
Q86.0 FAS (dysmorphic)—no further description offered for this specific code
F06.30 Mood disorder due to known physiological condition, unspecified
P00.4 Newborn (suspected to be) affected by maternal nutritional disorders
P01.9 Newborn (suspected to be) affected by maternal complication of pregnancy, unspecified
G93.4 Encephalopathy, other and unspecified (static)
G96.8 Other specified disorders of central nervous system
G96.9 Disorder of central nervous system, unspecified
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calculate entry age. For all values calculated in our study, a two-tailed p value of < 0.05 was considered statistically 
significant. All statistical analyses were conducted using SAS (ver. 9.4).
Statement. All methods were performed in accordance with relevant guidelines and regulations. All 
experimental protocols were approved by the Institutional Review Board of Yonsei University’s Health System 
(Y-2019–0174). The need for informed consent was waived since the NHIS-NSC provides anonymous cohort 
data to researchers for scholarly use.
Results
Table 2 shows the general characteristics and distribution of the FASD case group and matched controls. The case 
group included 3,103 individuals, while the control group included 15,515 individuals. The case group consisted 
of 16.7% of the study population while the control group consisted of 83.3% of the study population. Chi-square 
test values were used to compare the FASD case group to the control group.
Table 3 shows the general characteristics and distribution of hospitalizations and all-cause mortality, attained 
through univariate analysis. Among the 3,103 FASD cases, 27.5% (n = 853) experienced hospitalizations and 
12.5% (n = 387) died. 20.52% of hospitalizations and 21.35% of mortalities were attributable to FASDs in this 
population.
Among the control group, 10.8% (n = 1,673) experienced hospitalizations and 4.7% (736) died. Overall, 
13.6% of our study population experienced some form of hospitalization during the study period, while 6.0% 
died from various causes.
Table 4 shows the results of the Cox proportional hazards analysis of the FASD group and controls with 
attained age as the underlying timescale, while adjusting for covariates. Compared to the control group, FASD 
cases had increased risk of hospitalizations (HR: 1.25, 95% CI: 1.05–1.49, p = 0.0114) and all-cause mortality 
(HR: 1.33, 95% CI: 1.07–1.67, p = 0.0118). Regarding hospitalizations, compared to individuals with corporate 
insurance coverage, individuals with regional insurance coverage had slightly increased risk of hospitalization 
(HR: 1.12, 95% CI: 1.02–1.22, p = 0.0157).
Table 5 shows the results of the subgroup analyses for the impact of FASDs on various cause-specific hospitali-
zations while adjusting for sex, income, medical insurance, disability, disability severity, disability type, Charlson 
Comorbidity Index  Score28, region, and year of cohort diagnosis. Of the 2,526 ever hospitalizations that occurred 
within our study period, 27.5% of FASD patients and 10.8% of the general population controls experienced hospi-
talizations. The most common cause for hospitalization was diseases of the nervous system, which FASD patients 
showed a 52-fold increase for hospitalizations than their peers (HR: 51.78, 95% CI: 29.09–92.17, p < 0.0001).
Table 6 shows the results of the subgroup analyses for the impact of FASDs on various cause-specific mortal-
ity cases. Of the 1,123 deaths that occurred within our study period, 12.5% of FASD patients and 4.7% of the 
general population controls experienced death. The most common cause for mortality was neoplasms although 
Figure 1.  Flow chart of the study population.
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Table 2.  General characteristics of study population with FASD and general population. *Kidney, 








p-valuen % n % n %
Sex
Male 9057 48.6 1364 44.0 7693 49.6  < .0001
Female 9561 51.4 1739 56.0 7822 50.4
Age at Baseline
 < 20 5565 29.9 313 10.1 5252 33.9  < .0001
20–29 2672 14.4 265 8.5 2407 15.5
30–39 3091 16.6 399 12.9 2692 17.4
40–49 2838 15.2 599 19.3 2239 14.4
50–59 1819 9.8 556 17.9 1263 8.1
60–69 1490 8.0 551 17.8 939 6.1
 ≥ 70 1143 6.1 420 13.5 723 4.7
Income
None 513 2.8 114 3.7 399 2.6
Low 2140 11.5 366 11.8 1774 11.4  < .0001
Medium–low 2806 15.1 451 14.5 2355 15.2
Medium 3640 19.6 541 17.4 3099 20.0
Medium–high 4496 24.1 695 22.4 3801 24.5
High 5023 27.0 936 30.2 4087 26.3
Medical Insurance
Medical Aid 513 2.8 114 3.7 399 2.6
Insurance (Regional) 8632 46.4 1428 46.0 7204 46.4 0.0028
Insurance (Corporate) 9473 50.9 1561 50.3 7912 51.0
Disability Type
None 17,865 96.0 2783 89.7 15,082 97.2  < .0001
Mental 492 2.6 219 7.1 273 1.8
Sensory 122 0.7 38 1.2 84 0.5
Intellectual 69 0.4 28 0.9 41 0.3
Other* 70 0.4 35 1.1 35 0.2  < .0001
Disability Severity
No Disability 17,865 96.0 2783 89.7 15,082 97.2
Level 1–2 301 1.6 156 5.0 145 0.9
Level 3–6 452 2.4 164 5.3 288 1.9
Charlson Comorbidity Index
None 4547 24.4 249 8.0 4298 27.7  < .0001
One 4649 25.0 367 11.8 4282 27.6
Two 2465 13.2 339 10.9 2126 13.7
 ≥ Three 6957 37.4 2,148 69.2 4809 31.0
Region
Metropolitan 8123 43.6 1,583 51.0 6540 42.2  < .0001
City 4730 25.4 601 19.4 4129 26.6
Other 5765 31.0 919 29.6 4846 31.2
Year of Cohort Entry
2003 11,398 61.2 172 5.5 11,226 72.4  < .0001
2004 1740 9.3 180 5.8 1560 10.1
2005 942 5.1 192 6.2 750 4.8
2006 676 3.6 255 8.2 421 2.7
2007 589 3.2 287 9.2 302 1.9
2008 715 3.8 333 10.7 382 2.5
2009 497 2.7 283 9.1 214 1.4
2010 529 2.8 339 10.9 190 1.2
2011 583 3.1 397 12.8 186 1.2
2012 546 2.9 386 12.4 160 1.0
2013 403 2.2 279 9.0 124 0.8
Total 18,618 100.0 3103 100.0 15,515 100.0
6
Vol:.(1234567890)










PAR %n % n % Lower Upper n % n % Lower Upper
Fetal Alcohol Spectrum Disorder
None 1,673 10.80 13,842 89.2 1.00 – – 736 4.7 14,779 95.3 1.00 – –
Fetal Alcohol 
Spectrum Disorder 853 27.50 2,250 72.5 2.55 2.37 – 2.74 20.52 387 12.5 2,716 87.5 2.63 2.63 – 2.63 21.35
Sex
Male 1,197 13.20 7,860 86.8 1.00 – – 616 6.8 8,441 93.2 1.00 – –
Female 1,329 13.90 8,232 86.1 1.05 0.98 – 1.13 2.59 507 5.3 9,054 94.7 0.78 0.78 – 0.78 –12.76
Age at Baseline
 < 20 424 7.60 5,141 92.4 1.00 – – 8 0.1 5,557 99.9 1.00 – –
20–29 257 9.60 2,415 90.4 1.26 1.09 – 1.46 7.84 12 0.4 2,660 99.6 3.12 3.12 – 3.12 40.79
30–39 336 10.90 2,755 89.1 1.43 1.25 – 1.63 13.22 27 0.9 3,064 99.1 6.08 6.08 – 6.08 64.45
40–49 414 14.60 2,424 85.4 1.91 1.69 – 2.18 23.60 72 2.5 2,766 97.5 17.65 8.51 – 36.59 84.90
50–59 320 17.60 1,499 82.4 2.31 2.02 – 2.64 24.38 125 6.9 1,694 93.1 47.80 23.44 – 97.51 92.02
60–69 370 24.80 1,120 75.2 3.26 2.87 – 3.70 32.30 212 14.2 1,278 85.8 98.97 48.97 – 200.03 95.39
 ≥ 70 405 35.40 738 64.6 4.65 4.12 – 5.25 38.35 667 58.4 476 41.6 405.93 202.76 – 812.71 98.57
Income
None 115 22.40 398 77.6 1.00 – – 111 21.6 402 78.4 1.00 – –
Low 320 14.95 1,820 85 1.25 1.04 – 1.51 14.81 138 6.4 2,002 93.6 0.30 0.24 – 0.38 –130.54
Medium–low 392 13.97 2,414 86 2.17 1.82 – 2.59 41.68 147 5.2 2,659 94.8 0.24 0.19 – 0.30 –178.35
Medium 455 12.50 3,185 87.5 0.56 0.46 – 0.67 –63.33 173 4.8 3,467 95.2 0.22 0.18 – 0.27 –216.41
Medium–high 575 12.79 3,921 87.2 0.57 0.48 – 0.68 –62.74 199 4.4 4,297 95.6 0.20 0.17 – 0.25 –249.62
High 669 13.32 4,354 86.7 0.59 0.50 – 0.71 –58.29 355 7.1 4,668 92.9 0.33 0.27 – 0.40 –157.05
Medical Insurance
Medical Aid 115 22.40 398 77.6 1.74 1.47 – 2.07 3.68 111 21.6 402 78.4 3.31 2.76 – 3.96 10.59
Insurance 
(Regional) 1,193 13.80 7,439 86.2 1.07 1.00 – 1.16 3.45 392 4.5 8,240 95.5 0.69 0.61 – 0.78 –17.09
Insurance (Cor-
porate) 1,218 12.90 8,255 87.1 1.00 – – 620 6.5 8,853 93.5 1.00 – –
Disability Type
None 2,266 12.70 15,599 87.3 1.00 – – 828 4.6 17,037 95.4 1.00 – –
Mental 171 34.80 321 65.2 2.74 2.41 – 3.11 4.46 184 37.4 308 62.6 8.07 7.07 – 9.21 15.93
Sensory 36 29.50 86 70.5 2.33 1.76 – 3.07 0.89 45 36.9 77 63.1 7.96 6.25 – 10.13 4.51
Intellectual 19 27.50 50 72.5 2.17 1.48 – 3.19 0.45 12 17.4 57 82.6 3.75 2.23 – 6.30 1.05
Other* 34 48.60 36 51.4 3.83 3.00 – 4.89 1.09 54 77.1 16 22.9 16.64 14.41 – 19.22 5.75
Disability Severity
No Disability 2,266 12.70 15,599 87.3 1.00 – – 828 4.6 17,037 95.4 1.00 – –
Level 1–2 120 39.90 181 60.1 3.14 2.72 – 3.63 3.43 150 49.8 151 50.2 10.75 9.43 – 12.26 13.91
Level 3–6 140 31.00 312 69 2.44 2.12 – 2.82 3.44 145 32.1 307 67.9 6.92 5.96 – 8.04 12.75
Charlson Comorbidity Index
None 280 6.20 4,267 93.8 1.00 – – 116 2.6 4,431 97.4 1.00 – –
One 412 8.90 4,237 91.1 1.44 1.24 – 1.67 18.17 111 2.4 4,538 97.6 0.94 0.72 – 1.21 -3.35
Two 299 12.10 2,166 87.9 1.97 1.69 – 2.30 25.42 135 5.5 2,330 94.5 2.15 1.68 – 2.74 28.73
 ≥ Three 1,535 22.10 5,422 77.9 3.58 3.17 – 4.05 60.97 761 10.9 6,196 89.1 4.29 3.54 – 5.19 66.54
Region
Metropolitan 764 9.40 7,359 90.6 1.00 – – 440 5.4 7,683 94.6 1.00 – –
City 609 12.90 4,121 87.1 1.37 1.24 – 1.51 11.95 249 5.3 4,481 94.7 0.97 0.84 – 1.13 –1.05
Other 1,153 20.00 4,612 80 2.13 1.95 – 2.32 0.04 434 7.5 5,331 92.5 1.39 1.22 – 1.58 13.93
Year of Cohort Entry
2003 1,276 11.20 10,122 88.8 1.00 – – 632 5.5 10,766 94.5 1.00 – –
2004 196 11.30 1,544 88.7 1.01 0.87 – 1.16 0.08 83 4.8 1,657 95.2 0.86 0.69 – 1.08 –1.87
2005 124 13.20 818 86.8 1.18 0.99 – 1.40 1.32 59 6.3 883 93.7 1.13 0.87 – 1.46 0.99
2006 85 12.60 591 87.4 1.12 0.91 – 1.38 0.68 56 8.3 620 91.7 1.08 0.83 – 1.40 0.58
2007 117 19.90 472 80.1 1.77 1.50 – 2.10 3.67 50 8.5 539 91.5 1.53 1.16 – 2.02 2.55
2008 147 20.60 568 79.4 1.84 1.58 – 2.14 4.71 87 12.2 628 87.8 2.20 1.78 – 2.71 6.59
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FASD patients did not have increased risk of neoplasm mortality than the general population (HR: 0.88, 95% 
CI: 0.59–1.32, p < 0.0001). FASD patients had greatest risk of mortality from diseases of the nervous system (HR: 
4.15, 95% CI: 1.54–11.17, p = 0.0049) than their peers. Compared to their general population peers, FASD cases 
also had increased risk of mortality from circulatory (HR: 2.07, 95% CI: 1.34–3.18, p < 0.0001), digestive (HR: 
3.63, 95% CI: 1.66–7.93, p = 0.0012), respiratory (HR: 2.51, 95% CI: 1.15–5.48, p = 0.0215), and endocrine (HR: 
3.04, 95% CI: 1.33–6.96, p = 0.0085) diseases.
Table 7 shows the results of the subgroup analyses for the impact of the various types of FASDs on all-cause 
mortality. Compared to the control group, FASD cases diagnosed with ‘F06.30′ i.e. mood disorder due to known 
physiological condition, unspecified (HR: 1.30, 95% CI: 1.03–1.65, p = 0.0308), ‘G96.8′ i.e. other specified dis-
orders of the central nervous system (HR: 2.15, 95% CI: 1.29–3.59, p = 0.0035), and ‘G96.9′ i.e. disorder of cen-
tral nervous system, unspecified (HR: 1.77, 95% CI: 1.30–2.40, p = 0.0002) had increased hospitalization risk. 
Compared to the control group, FASD cases diagnosed with ‘G93.4′ i.e. encephalopathy, other and unspecified 
(static) (HR: 1.49, 95% CI: 1.17–1.91, p = 0.0014) and ‘G96.8′ i.e. other specified disorders of the central nervous 
system (HR: 2.04, 95% CI: 1.03–4.07, p = 0.0422) had increased mortality risk.
Discussion
Ultimately, the aim of our investigation was to investigate the impact of FASD diagnosis on hospitalizations 
and mortality compared to the general population. A major strenght of our investigation is that we were able to 
reference data from the NHIS claims database for the years 2003 and 2013, making our data representative of 
approximately 2% of the Korean population. Few studies have employed a dataset of this size to investigate the 
effects of FASD diagnosis on individuals’ health statuse. Furthermore, we were able to gather data for medical 
treatment records with diagnosis codes, giving us the opportunity to analyze the morbidity and mortality preva-
lence and hazard ratios of individuals cause-specifically (via ICD-10 codes implemented in electronic health 
records by healthcare professionals).
Because such few studies have attempted to investigate FASDs in South Korea and other countries, our analysis 
is unique in that prevalence of diagnosis, as well as cause-specific and all-cause hospitalizations and mortality 
could be calculated for. However, a number of limitations must be noted. Age is only presented in the NHIS-
NSC in five-year intervals; thus, we had to employ a median value for the entry and exit age of all subjects. It is 
highly recommended that future studies employing attained age as the time scale employ data with exact age of 
cohort entry, cohort exit, and diagnosis.
While the concept of hospitalizations has been employed in many previous studies, more studies are required 
to investigate how FASD patients differ from the general population with regard to hospitalization-reated char-
acteristics like length of stay, medical costs etc. to further this investigation.
In our study, insurance claims were the only source of information to gather a large sample size for FASDs, 
however, severity of the disease, social factors, patients’concerns and expectations are all factors that are impos-
sible to control for in such  situations30. Rashidian and colleagues have emphasized that while ICD codes are 
imputed by professionals who are trained and certified, there is substantial variability in human coding, as well 
as the identification and documentation of disease by different  clinicians31. In the case of neurobehavioral dis-
orders associated with prenatal alcohol exposure like fetal alcohol spectrum disorders, the only relevant terms 
to conditions within FASDs, as used in our investigation, are “fetal alcohol syndrome, dysmorphic” (Q86.0), 
and “newborn (suspected to be) affected by maternal use of alcohol” (P04.3), which are limited in describing the 
lifelong symptoms of PAE relative to FASDs.
Moreover, FASDs in nature have been difficult to diagnose as they co-occur or have similar symptoms to 
other attentional, neurocognitive, and/or adaptive function deficit disorders like attention-deficit/hyperactivity 
disorder (ADHD) or Down’s  Syndrome32. Certain symptoms have been likened to mood problems found in 
individuals with bipolar disorder and depressive disorders, and require ongoing identification of prenatal alcohol 
exposure, substance abuse or dependence, growth delay and central nervous system anomalies to distinguish 
from other  pathologies33.
Likewise, while most cases of FASDs cannot be identified in infancy, no useful criteria for adults or the elderly 
have currently been validified. As highlighted by Burd (2016), we need to figure out how to identify FASDs in 
adults and the elderly, especially because FASD symptoms among the elderly do not seem to resemble that of 
children and  adolescents7.
Additionally, while there are ICD-10 codes for FAS, no exact code exists for FASDs, and requires the researcher 









PAR %n % n % Lower Upper n % n % Lower Upper
2010 115 21.70 414 78.3 1.94 1.64 – 2.30 4.01 43 8.1 486 91.9 1.47 1.09 – 1.97 2.03
2011 145 24.90 438 75.1 2.22 1.91 – 2.58 5.61 35 6 548 94 1.08 0.78 – 1.51 0.41
2012 128 23.40 418 76.6 2.09 1.78 – 2.46 4.76 28 5.1 518 94.9 0.93 0.64 – 1.34 –0.34
2013 98 24.30 305 75.7 2.17 1.81 – 2.60 3.85 12 3 391 97 0.54 0.31 – 0.94 –1.60
Total 2,526 13.60 16,092 86.4 1,123 6 17,495 94
Table 3.  General Characteristics of Study Population by Hospitalizations and All-Cause Mortality. *Kidney, 
musculoskeletal, circulatory, respiratory, nervous system, developmental etc.
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Table 4.  Results of Cox Model for FASD and Hospitalizations/Mortality with Attained Age as Underlying 






p-valueLower Upper Lower Upper
Fetal Alcohol Spectrum Disorder
None 1.00 – – 1.00 – –
Fetal Alcohol Spectrum Disorder 1.25 1.05 – 1.49 0.0114 1.33 1.07 – 1.67 0.0118
Sex
Male 1.00 – – 1.00 – –
Female 1.01 0.93 – 1.11 0.7905 0.60 0.52 – 0.68  < .0001
Income
None 1.15 0.86 – 1.53 0.3392 1.57 1.15 – 2.12 0.0040
Low 1.01 0.86 – 1.19 0.8948 0.68 0.53 – 0.88 0.0033
Medium–low 1.08 0.93 – 1.26 0.3094 0.84 0.66 – 1.08 0.1722
Medium 1.00 – – 1.00 – –
Medium–high 1.04 0.91 – 1.20 0.5428 0.73 0.58 – 0.92 0.0066
High 1.00 0.88 – 1.15 0.9822 0.72 0.58 – 0.88 0.0018
Medical Insurance
Medical Aid – –
Insurance (Regional) 1.12 1.02 – 1.22 0.0157 0.94 0.81 – 1.09 0.3999
Insurance (Corporate) 1.00 – – 1.00 – –
Disability Type
None 1.00 – – 1.00 – –
Mental 1.44 1.14 – 1.82 0.0020 1.93 1.53 – 2.42  < .0001
Sensory 1.23 0.81 – 1.86 0.3322 1.15 0.80 – 1.65 0.4668
Intellectual 2.20 1.23 – 3.95 0.0081 3.77 1.85 – 7.69 0.0003
Other* 2.19 1.35 – 3.56 0.0016 2.63 1.84 – 3.75  < .0001
Disability Severity
No Disability 1.00 – – 1.00 – –
Level 1–2 1.24 0.91 – 1.70 0.1797 1.81 1.39 – 2.36  < .0001
Level 3–6 – –
Charlson Comorbidity Index
None 1.00 – – 1.00 – –
One 1.42 1.19 – 1.68  < .0001 0.69 0.50 – 0.94 0.0197
Two 1.84 1.53 – 2.20  < .0001 0.84 0.63 – 1.13 0.2552
 ≥ Three 2.75 2.36 – 3.21  < .0001 0.73 0.57 – 0.94 0.0145
Region
Metropolitan 1.00 – – 1.00 – –
City 1.58 1.40 – 1.78  < .0001 1.01 0.85 – 1.21 0.9054
Other 2.41 2.17 – 2.68  < .0001 1.02 0.87 – 1.18 0.8263
Year of Cohort Entry
2003 1.00 – – 1.00 – –
2004 1.57 1.33 – 1.84  < .0001 1.23 0.95 – 1.59 0.1236
2005 2.52 2.05 – 3.11  < .0001 1.43 1.04 – 1.97 0.0259
2006 2.94 2.23 – 3.86  < .0001 1.62 1.12 – 2.35 0.0105
2007 5.97 4.55 – 7.82  < .0001 1.53 1.05 – 2.21 0.0265
2008 7.77 5.95 – 10.16  < .0001 2.11 1.53 – 2.92  < .0001
2009 8.33 5.96 – 11.64  < .0001 2.35 1.54 – 3.57  < .0001
2010 16.72 12.09 – 23.12  < .0001 2.62 1.71 – 4.03  < .0001
2011 19.84 13.60 – 28.93  < .0001 1.86 1.12 – 3.09 0.0171
2012 16.42 9.26 – 29.13  < .0001 2.70 1.35 – 5.39 0.0050
2013 – – –
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literature review, records that can be reviewed for prenatal alcohol exposure range from newborn history forms, 
admission history and physical examinations, progress notes and discharge physical examinations, to obstetrical 
records of the obstetric nurses’ labor and delivery admission checklist and progress  notes34. However, there are 
substantial limitations to recording notations regarding the use of alcohol, cigarettes, recreational drugs, and/or 
harmful medications as ICD-10 codes for FAS are  limited34.
Because of the nature of the dataset, we were unable to control for certain confounding characteristics that 
may have been associated with FASD diagnosis and mortality, such as the drinking behaviors of the mother or 
father of the patient, or knowledge of prenatal alcohol exposure. Had details regarding drinking frequency and/
or amount during pregnancy been controlled for, associations between exposure to lesser amounts of alcohol 
and hospitalizations and mortality could have been investigated.
Previous studies have found that exposure to smaller amounts of alcohol are associated with significant fetal 
effects including reduction in birth weight, birth length, and head circumference; the presence of the typical 
alcohol-related craniofacial features; and significant cognitive and behavioral  manifestations34. Likewise, prenatal 
alcohol exposure, even in small amounts, has been associated with cranofacial development problems; especially 
among mothers who feel the effects of alcohol quickly, and who drink throughout  pregnancy35. Cranofacial 
abnormalities ranging from an elevation of the lower portion of the nose, smooting of the philtrum, reduced 
palpebral fissure length, midfacial hypoplasia, and retrognathia, have been strongly prevalent among infants of 
mothers who drank moderately during their first trimester of  pregnancy35.
Although disability severity and type were controlled for, we were unable to obtain exact information regard-
ing the severity of FASDs in patients’ lives with regard to primary and secondary disabilities.
Table 5.  Results of Subgroup Analysis on Impact of FASDs on Hospitalization, stratified by Hospitalization 










p-valuen % n % Lower Upper
Hospitalization Causes
All-Causes 853 27.5 1,673 10.8 1.00 1.25 1.05 – 1.49 0.0114
Nervous 450 14.5 18 0.1 1.00 51.78 29.09 – 92.17  < .0001
Mental 179 5.8 32 0.1 1.00 7.87 4.34 – 14.26  < .0001
Circulatory 59 1.9 112 0.5 1.00 1.18 0.67 – 2.09 0.5748
Abnormal 32 1.0 26 0.1 1.00 1.97 0.72 – 5.38 0.1861
Musculoskeletal 31 1.0 138 0.6 1.00 0.33 0.16 – 0.68 0.0027
Digestive 23 0.7 135 0.6 1.00 0.30 0.14 – 0.63 0.0014
Neoplasm 22 0.7 19 0.1 1.00 0.94 0.27 – 3.23 0.9230
Eye and Ear 17 0.5 158 0.7 1.00 0.41 0.19 – 0.88 0.0227
Endocrine 11 0.4 35 0.2 1.00 0.41 0.11 – 1.55 0.1878
Other* 29 0.9 1,000 .4 1.00 0.08 0.05 – 0.14  < .0001
Table 6.  Results of Subgroup Analysis on Impact of FASDs on Mortality, stratified by Mortality Cause. 










p-valuen % n % Lower Upper
Mortality Causes
All-Causes 387 12.5 736 4.7 1.00 1.33 1.07 – 1.67 0.0118
Neoplasm 94 3.0 234 1.5 1.00 0.88 0.59 – 1.32  < .0001
Circulatory 89 2.9 151 1.0 1.00 2.07 1.34 – 3.18  < .0001
Digestive 35 1.1 30 0.2 1.00 3.63 1.66 – 7.93 0.0012
Respiratory 31 1.0 36 0.2 1.00 2.51 1.15 – 5.48 0.0215
Endocrine 29 0.9 33 0.2 1.00 3.04 1.33 – 6.96 0.0085
Nervous 26 0.8 19 0.1 1.00 4.15 1.54 – 11.17 0.0049
External* 25 0.8 94 0.6 1.00 1.26 0.65 – 2.44 0.4957
Abnormal 20 0.6 73 0.5 1.00 0.77 0.32 – 1.85 0.5590
Infectious 17 0.5 22 0.1 1.00 2.22 0.72 – 6.81 0.1647
Other** 21 0.7 44 0.3 1.00 0.77 0.72 – 0.82  < .0001
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We were also unable to control for the exact date of diagnosis, which warrants future research as previous 
studies have acknowledged a strong association between early diagnosis of FASDs and fewer primary and/or 
secondary disabilities such as alcohol/drug problems, trouble with the law, and/or  confinement36. Fetal alcohol 
biomarkers and genetic research are believed to play a central role in determining the onset of FASDs, however, 
due to the nature of our dataset, we were unable to control for related variables. Considerably more research 
regarding this area is  warranted37.
Finally, while controlling for age was the main aim of our research design, it was impossible to control for 
the proportion of mortality events that occurred before the case could be identified. As noted in previous stud-
ies, prenatal alcohol exposure is associated with increased risk of various birth outcomes, including stillbirths, 
miscarriage, and sudden infant death  syndrome38,39. Because our sample was obtained through ICD-10 diagnoses 
that were obtained throughout over 10 years of follow up, some forms of survival bias will exist and this should 
be considered when interpreting results.
Despite these limitations, this study was able to demonstrate that compared to their general population peers, 
individuals with FASDs have increased risk of both hospitalizations and mortality, even when age effects are 
controlled for. As seen in Supplementary Tables 1 and 2, both hospitalizations and mortality among individuals 
with FASDs were affected by age effects, which resulted in different hazard ratios between the two study designs.
With our subgroup analyses, we were also able to see that men with FASDs have increased risk of hospitaliza-
tion compared to men without FASDs, and women with FASDs have increased risk of mortality compared to 
women without FASDs. Similarly, those in medium–high income groups have increased risk of hospitalizations 
compared to their general population peers when diagnosed with FASDs, as do those with no disability diagnosis. 
Finally, individuals with one comorbidity may have increased risk of mortality compared to the general popula-
tion, as well as those living in regions that are not in the city or metropolitan regions.
Furthermore, because of its population-based design and decade-long follow up, the study population is 
nationally representative. The NHIS-NSC database contains nationally representative population-based data 
on more than one million participants, generated by the government so that researchers and policymakers can 
access extensive information regarding electroic medical treatment bills, bill details, details of diseases, details of 
prescriptions, details of birth, and  deaths40. Selection bias is limited as the primary sampling unit is the individual 
and demographic characteristics are not lost as the sampling strategy is cohort based.
Through the use of a left truncated cohort with attained age as the time scale, we were able to avoid the 
biases that occur in time-on studies. Although starting points are relatively easy to identify for clinical studies, 
in epidemiological studies where the beginning of risk-periods are difficult to determine, time-scales may be 
warranted. Thiebaut and colleagues “strongly recommend not using time-on-study as the time scale for analysing 
epidemiologic cohort data”, especially when covariates of interest are either time-dependent or strongly associated 
with  age41. Since both these cases are true in our investigation and there is a substantial association between age 
and our covariate under study (FASD diagnosis), it was important to address these biases in our model.
Lastly, we employed objective indicators including the hospitalization index, which scholars have confirmed 
to be an indicator of primary care quality, when appropriate adjustment factors are applied  for28.
With regard to hospitalizations, we found that FASD diagnosis is associated with increased risk of hospitaliza-
tions, especially pertaining to diseases of the nervous system and mental diseases. With regard to mortality, we 
found that FASD diagnosis is associated with increased risk of mortality associated with circulatory, digestive, 
respiratory, endocrine, and nervous-system diseases.
Table 7.  Results of Subgroup Analyses on Type of FASD and Hospitalizations/Mortality. *P04.3 Newborn 
(suspected to be) affected by maternal use of alcohol (excludes FAS). Q86.0 FAS (dysmorphic)—no further 
description offered for this specific code. F06.30 Mood disorder due to known physiological condition, 
unspecified. P00.4 Newborn (suspected to be) affected by maternal nutritional disorders. P01.9 Newborn 
(suspected to be) affected by maternal complication of pregnancy, unspecified. G93.4 Encephalopathy, other 








p-valuen % Lower Upper Lower Upper
Type of FASD
All Cases 3,103 100.0 1.00 1.25 1.05 – 1.49 0.0114 1.33 1.07 – 1.67 0.0118
P04.3 1 0.0 1.00 – –
Q86.0 0 0.0 1.00 – –
F06.30 781 25.2 1.00 1.30 1.03 – 1.65 0.0308 1.17 0.87 – 1.57 0.3066
P00.4 0 0.0 1.00 – –
P01.9 3 0.1 1.00 – –
G93.4 2,015 64.9 1.00 1.10 0.91 – 1.33 0.3374 1.49 1.17 – 1.91 0.0014
G96.8 79 2.5 1.00 2.15 1.29 – 3.59 0.0035 2.04 1.03 – 4.07 0.0422
G96.9 224 7.2 1.00 1.77 1.30 – 2.40 0.0002 0.89 0.52 – 1.50 0.6485
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These results were somewhat expected as the association between prenatal alcohol exposure and increased 
immune-related risks have been proven in both animal and human studies over the last few  years42. Maternal 
alcohol ingestion has been associated with a two- to threefold increase in the risk of premature delivery for 
women who drink heavily or binge drink during  pregnancy43. Considering that premature delivery is linked to 
increased risk of respiratory infections, influenza, and  sepsis42, the association between FASD onset and increased 
risk of various diseases is unsurprising.
Like previous investigations, there was a great emphasis on the diagnosis of ‘mental and behavioral disorders’ 
(ICD-10 codes: F00-F99)9 among FASD patients and, in our population group, increased hospitalization and 
mortality risk were also associated with mental diseases.
However, surprisingly, deaths from external factors such as suicides, accidents, and poisoning by illegal drugs 
or alcohol were not associated with FASD diagnosis to a statistically significant degree in our study. Previous 
studies that have attributed mortality causes to the external, including suicides (15%) and accidents (14%) have 
proportionate increases, but more research must be done on associations between FASDs and these  causes23. 
Internally, diseases of the nervous and respiratory systems (8%), digestive system (7%), congenital malformations 
(7%), mental and behavioral disorders (4%), and diseases of the circulatory system (4%)23, were mostly in align-
ment with the proportion of deaths in our investigation. In our study, diseases of the circulatory system, diges-
tive system, and circulatory system were also one of the most common causes of death for FASD populations.
On the contrary, 3.0% of FASD deaths in our investigation were associated with various cancers, including 
digestive, respiratory, genital/urinary, and skin/bone/breast, which were not categorized in Than & Johnson’s 
investigation. It must be noted that in our study, suicide was not a major cause of mortality, which may be because 
our investigation looked at milder forms of FASDs compared to previous studies dealing with FAS, the most 
severe form of  FASDs23.
In the case of circulatory diseases, cerebrovascular and ischemic conditions were associated with increased 
mortality risk among individuals with FASDs. This was in alignment with the existing body of literature that has 
noted that individuals with FAS may manifest structural alterations, such as neural tube defects and alterations in 
neocortical or cerebellar  morphogenesis5. Because these alterations, especially with regard to cortical thickness, 
can indicate immature brain development and poorer general intellectual function ability, more in-depth studies 
are required regarding the association between FASD diagnosis and circulatory  function5.
While women had increased hospitalization risk than men, men had increased all-cause mortality risk than 
women. In existing studies regarding hospitalizations in South Korea, it has been clearly stated that several fac-
tors, including socioeconomic and demographic status, are central to the crude rate of hospitalizations. In one 
study, it was found that risk of hospitalizations and mortality increased among low income groups, those residing 
in rural  regions44. This was in alignment with our investigation where such individuals with lower SES were at 
increased risk of hospitalizations and death.
Of individuals with FASDs, we found that compared to their general population peers, those diagnosed with 
mood disorder due to known physiological condition, unspecified (F06.30), encephalopathy, and other and 
unspecified (static) (G93.4) had increased mortality risk.
While few studies have examined the types of FASDs in detail with regard to their association with cause-
specific mortality, in one clinic-based study in the past, it was found that the rate of maternal mortality for 
children with static encephalopathy was 8.8%, highlighting the risk of FASDs not only on the diagnosed child, 
but the mother as  well45. Encephalopathy diagnosis has also been associated with premature mortality among 
individuals with liver  cirrhosis46, birth asphyxia and trauma, and infantile epilepsy, with early infantile epileptic 
encephalopathy syndrome (EIEE), also known as Ohtahara syndrome, causing deaths in 58.8% of those diag-
nosed within one year of seizure  onset47.
Regarding the increased mortality risk of cancers, circulatory diseases, and respiratory diseases, more research 
regarding fetal/placental anomalies and their association with various carcinogens are warranted. Apropos of can-
cers, in one previous study of childhood cancer in children with various congenital anomalies, < 3% of children 
with anomalies were part of the fetal alcohol syndrome category, and thereby excluded from the final  analyses48.
Significant associations with alcohol exposure have already been made with congenital structural heart defects 
like ventricular septal defects, atrial septal defects, and conotruncal defects, and clinicians have reported some 
cases of children with FASDs whom asymptomatic cardiac rhythm alterations were detected in absence of struc-
tural cardiovascular system anomalies during routine follow-up49.
As emphasized by Onesimo and colleagues and seen in the results of our investigation where diseases of the 
circulatory system were of great mortality risk to FASD populations, an alert must be made for clinicians, given 
the possibility of finding anomalies of heart conduction and rhythm in children affected by FASDs even without 
structural congenital heart  disease49.
For clinicians, a thorough understanding of potential risk and protective factors may help in determining the 
ways in which to help with prevention and management of FASDs. As listed in the existing body of literature, 
risk factors associated with adverse life outcomes have ranged from the environmental (being over 12 years of 
age at FAS/FAE (fetal alcohol effects) diagnosis, having a ‘low’ percent of life in a stable/nurturing home, having 
an IQ ≥ 70, being a victim of physical, sexual abuse/domestic violence, having a ‘high’ percentage of life with 
another person abusing alcohol and/or drugs, and having a ‘high’ percentage of life where basic needs are not 
met) to sociodemographic (being male, suffering from FAE)25.
On the contrary, strong protective factors against various secondary disabilities like alcohol/drug problems 
and confinement have included living a high percent of one’s life in a stable/nurturing home, being diagnosed 
at a younger age, and having a diagnosis of  FAS25.
Overall, any alcohol consumption has consequences on craniofacial development, supporting advice that 
complete abstinence from alcohol during pregnancy is the safest  option35. Women must be advised to abstain 
from alcohol during pregnancy, even when drinking below the low-risk guidelines of their general population 
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counterparts. Equally, women with a past history of alcohol and/or substance abuse must also be provided with 
appropriate interventions to prevent continued drinking by healthcare professionals, if planning on pregnancy 
and/or childbirth.
Physicians and nurses are in an ideal position to advise against alcohol consumption during pregnancy, and 
inform a woman who is drinking early in her pregnancy about the injuries her alcohol consumption brings 
about to fetal cells, organs, and  limbs50. As more than one-half of all pregnancies in the United States are unin-
tended, women who have the potential to conceive should also be educated about the potential risks of frequent 
 drinking50. Primary care providers can also help those diagnosed with FAS or FASDs by informing them about 
the specific diseases, especially with regard to diseases of the nervous system and mental systems, for example 
that increase hospitalization and mortality risk.
Policymakers should also be aware that the lowering of alcohol taxes and relative reductions in the price 
of alcohol can result in an increase in alcohol-related hospitalizations, including maternal care for (suspected) 
fetal  damage51.
Although no cures currently exist for the treatment of FASDs, certain intervention services that may help, 
as recommended by certain medical centers, are as follows: (1) a team that includes a special education teacher, 
a speech therapist, physical and occupational therapists, and a psychologist; (2) early intervention to help with 
walking, talking and social skills; (3) special services in school to help with learning and behavioral issues; (4) 
medications to help with some symptoms; (5) medical care for health problems, such as vision problems or 
heart abnormalities; (6) addressing alcohol and other substance use problems, if needed; (7) vocational and life 
skills training; and (8) counseling to benefit parents and the family in dealing with a child’s behavioral problems.
Conclusion
The current study supplements the body of evidence regarding the lifelong adverse effects of prenatal alcohol 
exposure on those diagnosed with FASDs. By systematically analyzing the hospitalizations and mortality causes 
of those diagnosed, in comparison with their general population peers, vulnerable sociodemographic and health-
related characteristics were identified.
Although there are numerous limitations regarding our data and analogy, we believe that this study can have 
meaningful impact socially, politically, and economically, by raising awareness regarding the harms of FASDs 
and the risks involved with diagnosis. For South Korea, our study shows that the impact of FASDs affect a large 
proportion of hospitalizations and mortality. In our study population, around 20.52% of hospitalizations and 
21.35% of mortalities were attributable to FASDs. While this estimate may not be an accurate proportion of the 
effects of FASDs for the entire South Korean population as we had a limited number of random controls, such 
figures show the need for more research regarding the impact that this disease has for hospitalizations and deaths 
in different countries. Future research that incorporates international collaboration with countries where FASD 
research is relatively more active (e.g. Canada, United States, United Kingdom, Australia etc.) would refine the 
variability of our estimates.
Considering the occurrence of lifelong adverse outcomes associated with hospitalizations and mortality, clini-
cians and policymakers should make sure to emphasize to potential mothers the importance of temperance. This 
is particularly the case with certain diseases which showed a sharp increase in hospitalization and mortality risk 
among individuals with FASDs compared to the general population, such as diseases of the nervous system, men-
tal diseases, and diseases of the digestive system, circulatory system, respiratory system, and endocrine system.
It is also recommended that clinicians and policymakers invest in more research, especially with regard to 
cases of encephalopathy, disorders of the central nervous system, and mood disorders due to known physiological 
conditions which were FASD domains that showed an increase in hospitalization and mortality risk.
Finally, diagnostic clinics that provide for check-ups regarding circulatory and respiratory diseases, as well 
as provide funding for prevention programs (education, alcohol abuse treatment, advocacy, birth control) and 
long-term residential/job training programs/medical check-ups for individuals diagnosed with FASDs are neces-
sary for the prevention and management of excessive hospitalizations and mortality.
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